Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5025,181.20.81%H 25,390.8 · L 25,141.8upd. 1:22 PM IST|Sensex81,821.560.86%H 82,578.87 · L 81,816.96upd. 1:07 PM IST|Bank Nifty61,926.80.56%H 62,363.75 · L 61,765.45upd. 1:22 PM IST|USD / INR₹93.480.01%H ₹93.51 · L ₹93.23upd. 1:22 PM IST|Gold Intl (10g)₹1,13,200.262.53%H ₹1,15,989.31 · L ₹1,13,200.26upd. 1:12 PM IST|Silver Intl (1kg)₹1,37,574.453.34%H ₹1,42,833.99 · L ₹1,37,303.96upd. 1:12 PM IST|Crude WTI₹7,867.282.15%H ₹8,034.61 · L ₹7,829.88upd. 1:12 PM IST|Bitcoin₹60,44,9900.05%H ₹60,46,426.21 · L ₹60,43,553.79upd. 1:02 PM IST|Ethereum₹1,69,4320.9%H ₹1,70,193.81 · L ₹1,68,670.19upd. 1:02 PM IST|Nifty 5025,181.20.81%H 25,390.8 · L 25,141.8upd. 1:22 PM IST|Sensex81,821.560.86%H 82,578.87 · L 81,816.96upd. 1:07 PM IST|Bank Nifty61,926.80.56%H 62,363.75 · L 61,765.45upd. 1:22 PM IST|USD / INR₹93.480.01%H ₹93.51 · L ₹93.23upd. 1:22 PM IST|Gold Intl (10g)₹1,13,200.262.53%H ₹1,15,989.31 · L ₹1,13,200.26upd. 1:12 PM IST|Silver Intl (1kg)₹1,37,574.453.34%H ₹1,42,833.99 · L ₹1,37,303.96upd. 1:12 PM IST|Crude WTI₹7,867.282.15%H ₹8,034.61 · L ₹7,829.88upd. 1:12 PM IST|Bitcoin₹60,44,9900.05%H ₹60,46,426.21 · L ₹60,43,553.79upd. 1:02 PM IST|Ethereum₹1,69,4320.9%H ₹1,70,193.81 · L ₹1,68,670.19upd. 1:02 PM IST|
0%
real-estate

Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo

Arth Vani DeskPublished: 2 min read
Biocon Secures USFDA Approval for Breast Cancer Biosimilar Pebrilzo

Source: ET Real Estate

Arth Insight · What this means for your wallet

Immediate action
Review your investment portfolio's exposure to pharmaceutical stocks or funds.
  • For investors, this approval boosts Biocon's future revenue potential, positively impacting its stock performance and any mutual funds holding it.
  • While this approval is for the US, it signals Indian companies' ability to develop complex, affordable biosimilars, potentially reducing future high-cost drug treatments in India.
  • India's growing global leadership in biosimilars strengthens the domestic pharmaceutical sector, attracting investment and contributing to overall economic growth.
Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Indian biopharmaceutical major Biocon Ltd has received approval from the US Food and Drug Administration (USFDA) for its biosimilar Pebrilzo, a treatment for HER2-positive breast cancer. This milestone expands Biocon's US oncology biosimilar portfolio to five products, with a global launch agreement with Genentech set for 2028.

Key Highlights
  • ▸Biocon's Pebrilzo, a biosimilar for HER2-positive breast cancer, has received USFDA approval.
  • ▸This approval increases Biocon's US oncology biosimilar portfolio to five products.
  • ▸A global settlement with Genentech sets the earliest licensed launch date for Pebrilzo in 2028.
Key Takeaways
  • ✓Biocon's Pebrilzo, a biosimilar for HER2-positive breast cancer, has received USFDA approval.
  • ✓This approval increases Biocon's US oncology biosimilar portfolio to five products.
  • ✓A global settlement with Genentech sets the earliest licensed launch date for Pebrilzo in 2028.

Indian biopharmaceutical major Biocon Ltd has announced a significant regulatory achievement, securing approval from the US Food and Drug Administration (USFDA) for its biosimilar product, Pebrilzo. This approval marks a pivotal moment for Biocon, as Pebrilzo is designed to treat HER2-positive breast cancer, a specific and aggressive form of the disease.

The USFDA's nod for Pebrilzo substantially bolsters Biocon's presence in the competitive American oncology market. With this addition, the company's portfolio of oncology biosimilars approved in the United States now stands at five. This expansion underscores Biocon's commitment to developing and delivering advanced biological therapies that offer more affordable and accessible treatment options for patients.

What is Pebrilzo and its Significance?

Pebrilzo is a biosimilar, meaning it is highly similar to an already approved biological medicine (known as the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency. In this case, Pebrilzo is a biosimilar to Herceptin (trastuzumab), a cornerstone treatment for HER2-positive breast cancer. HER2-positive breast cancer is characterized by an overexpression of the human epidermal growth factor receptor 2 (HER2) protein, which promotes aggressive tumor growth. Targeted therapies like trastuzumab play a crucial role in improving outcomes for these patients.

The introduction of biosimilars like Pebrilzo is vital for the global healthcare landscape. They provide cost-effective alternatives to expensive innovator drugs, thereby increasing patient access to life-saving treatments and reducing the financial burden on healthcare systems and individuals. For India, a country focused on healthcare accessibility, an Indian company achieving such approvals on the global stage is a matter of national pride and signals growing capabilities in advanced biopharmaceutical research and manufacturing.

Global Launch Strategy and Future Outlook

Beyond the USFDA approval, Biocon has also reached a comprehensive global settlement with Genentech, the innovator company behind the reference product. This agreement secures an earliest licensed launch date for Pebrilzo in 2028. This long-term strategic settlement provides clarity on the product's market entry timeline and demonstrates Biocon's proactive approach to navigating the complex intellectual property landscape of biological medicines.

The year 2028 target launch allows Biocon ample time to prepare its global commercialization strategy, supply chain, and market penetration efforts across various territories. While the USFDA approval specifically pertains to the American market, the global settlement indicates a broader ambition for Pebrilzo's reach, potentially impacting millions of patients worldwide.

Biocon's Growing Biosimilar Footprint

Biocon Biologics, a subsidiary of Biocon Ltd, has been a pioneer and a significant player in the global biosimilar market. Their consistent success in securing regulatory approvals for complex biologics in highly regulated markets like the US and Europe highlights their robust research and development capabilities, manufacturing prowess, and stringent quality control standards. This latest approval for Pebrilzo further solidifies Biocon's position as a leading global biosimilar company, enhancing its reputation and potential for revenue growth.

For Indian investors, this news is a positive indicator of Biocon's strengthening product pipeline and its ability to compete effectively on an international scale. The company's focus on oncology, diabetes, and autoimmune diseases through biosimilars positions it well within high-growth therapeutic areas, promising long-term value creation.

This report is for informational purposes only and does not constitute investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
13.5%
3Y CAGR
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
12.8%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.7%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
12.2%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
11.9%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
11.4%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

What is Pebrilzo?

Pebrilzo is a biosimilar drug developed by Biocon, approved by the USFDA for treating HER2-positive breast cancer. It is highly similar to an existing approved biological medicine.

What does USFDA approval mean for Biocon?

The USFDA approval for Pebrilzo significantly strengthens Biocon's presence in the US oncology market, bringing its total approved oncology biosimilars to five and enhancing its global reputation as a biopharmaceutical leader.

When will Pebrilzo be available globally?

Following a global settlement with Genentech, the earliest licensed launch date for Biocon's Pebrilzo is set for 2028.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Hair Loss in India: Are Vitamin D, Iron, and B12 Deficiencies the Hidden Cause?
real-estate

Hair Loss in India: Are Vitamin D, Iron, and B12 Deficiencies the Hidden Cause?

Many Indians experiencing persistent hair loss might be overlooking a critical factor: nutritional deficiencies. Key vitamins and minerals like Vitamin D, iron, and B12 are essential for healthy hair, and their absence can manifest as tiredness, dry hair, or breakage, requiring professional diagnosis.

7h ago·2 min readListen
DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification
real-estate

DRI Searches Cipla's Mumbai Office, Bhiwandi Depot Over Imported Drug Classification

The Directorate of Revenue Intelligence (DRI) recently conducted searches at pharmaceutical major Cipla's Mumbai office and Bhiwandi depot. The searches were related to the classification or exemption of an imported finished pharmaceutical product. Cipla has stated its full cooperation with authorities and anticipates no significant financial or operational impact.

17h ago·1 min readListen
Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market
real-estate

Glenmark Launches Generic Kidney Cancer Drug in US, Targeting ₹4,490 Crore Market

Glenmark Pharmaceuticals Inc. U.S. has launched Axitinib Tablets, a generic version of Pfizer's Inlyta, in the United States for advanced kidney cancer treatment. This strategic move allows Glenmark to tap into a substantial market, with the original drug's annual sales previously reaching approximately ₹4,490 crore (USD 538.4 million) in the US.

1d ago·1 min readListen
From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey
real-estate

From Chartered Accountant to Fitness Guru: Dinaz Vervatwala's Wellness Journey

Dinaz Vervatwala, founder of Hyderabad's Dinaz's Fitness, transitioned from a chartered accountant to a prominent fitness and wellness coach. Her journey emphasizes holistic wellness, integrating mental health and sustainable practices, inspired by overcoming a personal accident.

4d ago·2 min readListen